{"id":"CHEMBL1081506","canonicalSmiles":"O=C1OC(OC(=O)c2cccnc2Nc2cccc(C(F)(F)F)c2)c2ccccc21","inchiKey":"ANMLJLFWUCQGKZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TALNIFLUMATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Somalgen"],"synonyms":["BA 7602-06","BA-7602-06","Talniflumate"],"crossReferences":{"PubChem":["144206137","170466420","50112890"],"drugbank":["DB09295"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1083659","canonicalSmiles":"Cc1ccc(-n2nccn2)c(C(=O)N2CCN(c3nc4cc(Cl)ccc4o3)CC[C@H]2C)c1","inchiKey":"JYTNQNCOQXFQPK-MRXNPFEDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SUVOREXANT","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Belsomra"],"synonyms":["MK-4305","MK4305","Suvorexant"],"crossReferences":{"DailyMed":["suvorexant"],"drugbank":["DB09034"],"chEBI":["82698"]},"linkedTargets":{"rows":["ENSG00000137252","ENSG00000121764"],"count":2},"linkedDiseases":{"rows":["EFO_0004319","EFO_0004262","EFO_0003768","EFO_0001358","EFO_0009267","EFO_0008568","EFO_0010702","EFO_0010445","EFO_0004698","EFO_0020916","MONDO_0004975","MONDO_0007079","EFO_0004270","EFO_0003877"],"count":14},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and is indicated for insomnia and has 9 investigational indications."}
{"id":"CHEMBL1095299","canonicalSmiles":"O=C(O)CCC(=O)OC1N=C(c2ccccc2Cl)c2cc(Br)ccc2NC1=O","inchiKey":"NQTRBZXDWMDXAQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CINAZEPAM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB14715"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1107","canonicalSmiles":"CCCCN(CCCC)CCC(O)c1cc2c(Cl)cc(Cl)cc2c2cc(C(F)(F)F)ccc12","inchiKey":"FOHHNHSLJDZUGQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HALOFANTRINE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["DL-WR-171669","Halofantrine"],"crossReferences":{"Wikipedia":["Halofantrine"],"drugbank":["DB01218"]},"childChemblIds":["CHEMBL1966423","CHEMBL1200901"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1992 and is indicated for malaria."}
{"id":"CHEMBL111575","canonicalSmiles":"N=C(N)c1ccc2cc(C(=O)Nc3cccc(OC4CCCC4)c3)ccc2c1","inchiKey":"FWTQOPWAMQXIMI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL111575","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07076"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1182743","canonicalSmiles":"CCOC(=O)c1c[n+](C)c2n(c1=O)C(C)CCC2","inchiKey":"JOWRFSPJFXLGGY-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RIMAZOLIUM","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Rimazolium","Rimazolium cation","Rimazolium ion"],"crossReferences":{"drugbank":["DB13289"]},"childChemblIds":["CHEMBL263807"],"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL1200685","canonicalSmiles":"[133Xe]","inchiKey":"FHNFHKCVQCLJFQ-NJFSPNSNSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"XENON XE 133","maximumClinicalTrialPhase":4,"parentId":"CHEMBL1236802","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Xeneisol","Xenon xe 133","Xenon xe 133 gas ampule","Xenon xe 133 gas vials","Xenon xe 133-v.s.s."],"synonyms":["133xe","Xenon (133 xe)","Xenon (133Xe) Gas","Xenon (133xe)","Xenon (133xe) gas","Xenon (133xe) injection","Xenon 133","Xenon xe 133","Xenon xe-133","Xenon, xe-133","Xenon,xe-133","Xenon-133"],"crossReferences":{"drugbank":["DB09315"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL1200863","canonicalSmiles":"Cl.N[C@@H](Cc1ccc(N(CCCl)CCCl)cc1)C(=O)O","inchiKey":"OUUYBRCCFUEMLH-YDALLXLXSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"MELPHALAN HYDROCHLORIDE","yearOfFirstApproval":1992,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL852","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alkeran","Evomela","Melphalan hydrochloride"],"synonyms":["Alkeran hydrochloride","CB 3025 HYDROCHLORIDE","CB-3025 HYDROCHLORIDE","Melphalan hcl","Melphalan hydrochloride","Sarcolysin hydrochloride, l-"],"crossReferences":{"DailyMed":["melphalan%20hydrochloride"],"PubChem":["301128"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1992 and has 14 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL1201200","drugType":"Small molecule","blackBoxWarning":false,"name":"GALLIUM","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Gallium"],"crossReferences":{"chEBI":["49631"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL1201231","canonicalSmiles":"C[C@]12C[C@H](O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)COP(=O)(O)O","inchiKey":"JDOZJEUDSLGTLU-VWUMJDOOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PREDNISOLONE PHOSPHORIC ACID","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Prednisolone phosphate","Prednisolone phosphoric acid"],"crossReferences":{"DailyMed":["prednisolone%20sodium%20phosphate"],"drugbank":["DB14631"]},"childChemblIds":["CHEMBL1201014"],"linkedTargets":{"rows":["ENSG00000113580"],"count":1},"linkedDiseases":{"rows":["EFO_0005854","HP_0000559","EFO_0000768","EFO_0003929","EFO_0009448","EFO_0007308","EFO_0000565","EFO_1001231","MP_0001845","MONDO_0002280","MONDO_0005301","EFO_1001226","EFO_0004255","EFO_0007126","MONDO_0004979","EFO_0000341","EFO_0007141","EFO_0007415"],"count":18},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 13 approved and 4 investigational indications."}
{"id":"CHEMBL1201396","canonicalSmiles":"C[C@@H]1C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)SCF","inchiKey":"MGNNYOODZCAHBA-GQKYHHCASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FLUTICASONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fluticasone"],"crossReferences":{"Wikipedia":["Fluticasone"],"drugbank":["DB13867"],"chEBI":["5134"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201405","canonicalSmiles":"COc1cc2c(cc1OC)CN(C(=O)[C@H](C)N[C@@H](CCc1ccccc1)C(=O)O)[C@H](C(=O)O)C2","inchiKey":"CMPAGYDKASJORH-YSSFQJQWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MOEXIPRILAT","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Moexipril related compound a","Moexiprilat","RS-10029"],"crossReferences":{"PubChem":["170466490"],"drugbank":["DB14210"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1201457","drugType":"Unknown","blackBoxWarning":false,"name":"CELLULOSE SODIUM PHOSPHATE","yearOfFirstApproval":1982,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Calcibind","Calcisorb"],"synonyms":["Cellulose disodium phosphate","Cellulose sodium phosphate","Sodium Cellulose Phosphate","Sodium cellulose phosphate"],"description":"Unknown drug with a maximum clinical trial phase of IV that was first approved in 1982."}
{"id":"CHEMBL1201625","drugType":"Small molecule","blackBoxWarning":false,"name":"CHOLESTYRAMINE","yearOfFirstApproval":1973,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Cholestyramine","Cholestyramine light","Cholybar","Duolite ap143 resin","Locholest","Locholest light","Prevalite","Questran","Questran light"],"synonyms":["A-3384","A3384","Cholestyramine","Cholestyramine resin","Colestyramine","Colestyramine 20","Cuemid"],"crossReferences":{"DailyMed":["cholestyramine"],"DrugCentral":["727"],"Wikipedia":["Cholestyramine"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1973 and has 3 approved and 7 investigational indications."}
{"id":"CHEMBL1201747","canonicalSmiles":"CN1CCC(=C2c3ccccc3CCn3c(C=O)cnc32)CC1","inchiKey":"MWTBKTRZPHJQLH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ALCAFTADINE","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Lastacaft"],"synonyms":["Alcaftadine","R 89674","R-89674"],"crossReferences":{"DailyMed":["alcaftadine"],"Wikipedia":["Alcaftadine"],"drugbank":["DB06766"],"chEBI":["71023"]},"linkedTargets":{"rows":["ENSG00000196639"],"count":1},"linkedDiseases":{"rows":["EFO_0007141","EFO_0005751"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for allergic conjunctivitis and eye allergy."}
{"id":"CHEMBL1218","canonicalSmiles":"CCC(=O)NCC[C@@H]1CCc2ccc3c(c21)CCO3","inchiKey":"YLXDSYKOBKBWJQ-LBPRGKRZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"RAMELTEON","yearOfFirstApproval":2005,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ramelteon","Rozerem"],"synonyms":["Ramelteon","TAK-375","TAK375"],"crossReferences":{"DailyMed":["ramelteon"],"drugbank":["DB00980"]},"linkedTargets":{"rows":["ENSG00000168412","ENSG00000134640"],"count":2},"linkedDiseases":{"rows":["MONDO_0005090","EFO_0003768","EFO_0009516","EFO_0009267","EFO_0008568","EFO_0004698","MONDO_0100431","EFO_0007191","MONDO_0005277","EFO_0001422","EFO_0000289","EFO_0003890","MONDO_0100096","MONDO_0002050","MONDO_0005180","EFO_0000341","EFO_0003918","EFO_0005411","EFO_0007462","MONDO_0005475"],"count":20},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2005 and is indicated for insomnia and has 12 investigational indications."}
{"id":"CHEMBL1233960","canonicalSmiles":"O=C(NCCO)c1ccc(Cl)cc1","inchiKey":"GBARCMIFTACERW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1233960","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["4252831","91410"],"drugbank":["DB08082"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1234282","canonicalSmiles":"CO[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O","inchiKey":"OHWCAVRRXKJCRB-CXNFULCWSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1234282","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03879"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1235237","canonicalSmiles":"COc1ccc(-c2nc(-c3cccs3)[nH]c2-c2ccc(OC)cc2)cc1","inchiKey":"XBMULXNXJLWLLD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL1235237","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08383"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1318341","canonicalSmiles":"Cc1cc2c(cc1S(N)(=O)=O)S(=O)(=O)CCC2","inchiKey":"FNQQBFNIYODEMB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"METICRANE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Arresten","Meticrane","NSC-759309","SD 17102","SD-17102"],"crossReferences":{"PubChem":["11112466","144204046","170465801","56463348"],"drugbank":["DB13284"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL1360","canonicalSmiles":"COc1ccc(CC2c3cc(OC)c(OC)cc3CC[N+]2(C)CCC(=O)OCCCCCOC(=O)CC[N+]2(C)CCc3cc(OC)c(OC)cc3C2Cc2ccc(OC)c(OC)c2)cc1OC","inchiKey":"YXSLJKQTIDHPOT-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ATRACURIUM","yearOfFirstApproval":1983,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Atracurium","Atracurium cation","Atracurium ion","Tracrium"],"crossReferences":{"DailyMed":["atracurium%20besylate"],"Wikipedia":["Atracurium_besilate"],"chEBI":["2914"]},"childChemblIds":["CHEMBL4584552","CHEMBL1200527"],"linkedTargets":{"rows":["ENSG00000170175","ENSG00000138435","ENSG00000135902","ENSG00000108556","ENSG00000196811"],"count":5},"linkedDiseases":{"rows":["HP_0001336"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1983."}
{"id":"CHEMBL139393","canonicalSmiles":"O=C(O)C(=O)Nc1sc2c(c1C(=O)O)CCNC2","inchiKey":"ZIBMATWHOAGNTR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL139393","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB03670"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1452696","canonicalSmiles":"CC(C)=CCC1C(=O)N(c2ccccc2)N(c2ccccc2)C1=O","inchiKey":"RBBWCVQDXDFISW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FEPRAZONE","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["Germany"," United Kingdom"],"classes":["Dermatological toxicity"],"year":1984},"tradeNames":[],"synonyms":["DA 2370","DA-2370","Feprazone"],"crossReferences":{"PubChem":["144205761","170465969","26758004"],"drugbank":["DB13364"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and has 3 approved indications. It was withdrawn in Germany and  United Kingdom initially in 1984 due to Dermatological toxicity."}
{"id":"CHEMBL1453","canonicalSmiles":"C[C@]12CC[C@H](O)C[C@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)[C@@H](C3=CC(=O)OC3)CC[C@]12O","inchiKey":"XZTUSOXSLKTKJQ-CESUGQOBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIGITOXIGENIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Digitoxigenin","Digoxigenin","Uzarigenin"],"crossReferences":{"PubChem":["477480","56463036"],"Wikipedia":["Digitoxigenin"],"drugbank":["DB04177"],"chEBI":["42219"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL15192","canonicalSmiles":"CC1(C)CCC2=C(O1)c1ccccc1C(=O)C2=O","inchiKey":"QZPQTZZNNJUOLS-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LAPACHONE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".beta.-lapachone","ARQ 501","ARQ-501","Arq 501","Beta lapachone","Beta-Lapachone","Beta-lap-wj","Lapachone","Lapachone, Beta-","MB-12066","NSC-26326","NSC-629749"],"crossReferences":{"PubChem":["11111370","124880531","124880533","124880535","26753601","494711","50106535","50106536","50106537","85231108","90340897"],"drugbank":["DB11948"],"chEBI":["10429"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL157105","canonicalSmiles":"O=C(O)C1=C(C(=O)Nc2c(F)cc(-c3cccc(OC(F)(F)F)c3)cc2F)CCC1","inchiKey":"VTGXLCZUWFYELR-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL157105","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07975"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL1614725","canonicalSmiles":"CC(C)(O)CC(=O)NCCn1ccc2ncnc(Nc3ccc(Oc4cccc(C(F)(F)F)c4)c(Cl)c3)c21","inchiKey":"ZYQXEVJIFYIBHZ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TAK-285","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TAK-285","Tak 285","Tak-285","Tak285"],"linkedTargets":{"rows":["ENSG00000146648","ENSG00000141736"],"count":2},"linkedDiseases":{"rows":["EFO_0000311"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL16476","canonicalSmiles":"CC(C)NCC(O)c1ccc2ccccc2c1","inchiKey":"HRSANNODOVBCST-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRONETALOL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United Kingdom"],"classes":["Carcinogenicity"],"year":1965},"tradeNames":[],"synonyms":["AY 6204 [AS HYDROCHLORIDE]","AY-6204 HCL","Dl-pronethalol","GNF-PF-2670","ICI 38174 [AS HYDROCHLORIDE]","Inetol","Naphthylisoproterenol","Nethalide","Pronetalol","Pronethalol"],"crossReferences":{"PubChem":["144204478","170466606","26751909"],"chEBI":["8463"]},"childChemblIds":["CHEMBL1876082"],"description":"Small molecule drug with a maximum clinical trial phase of IV. It was withdrawn in United Kingdom  in 1965 due to Carcinogenicity."}
{"id":"CHEMBL1743022","drugType":"Antibody","blackBoxWarning":false,"name":"FRESOLIMUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fresolimumab","GC-1008","GC1008","GZ-402669","GZ402669"],"linkedTargets":{"rows":["ENSG00000105329","ENSG00000119699","ENSG00000092969"],"count":3},"linkedDiseases":{"rows":["EFO_0000404","EFO_0000770","EFO_0000768","EFO_0000681","MONDO_0007254","EFO_0004236","Orphanet_666","EFO_0003833","EFO_0003060"],"count":9},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 9 investigational indications."}
{"id":"CHEMBL1754","canonicalSmiles":"CCN1CC(CCN2CCOCC2)C(c2ccccc2)(c2ccccc2)C1=O","inchiKey":"XFDJYSQDBULQSI-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DOXAPRAM","yearOfFirstApproval":1965,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["Docatone","Doxapram"],"crossReferences":{"DailyMed":["doxapram%20hydrochloride"],"PubChem":["50112713"],"Wikipedia":["Doxapram"],"drugbank":["DB00561"],"chEBI":["681848"]},"childChemblIds":["CHEMBL1200876","CHEMBL3989519"],"linkedTargets":{"rows":["ENSG00000169427","ENSG00000171303"],"count":2},"linkedDiseases":{"rows":["EFO_0009444","EFO_0004262","EFO_0000684","EFO_0003818","EFO_0003917","HP_0002104"],"count":6},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1965 and is indicated for respiratory system disease and lung disease and has 1 investigational indication."}
{"id":"CHEMBL1765291","canonicalSmiles":"CC(C(=O)O)c1ccc2c(c1)CC(=O)c1ccccc1S2","inchiKey":"MUXFZBHBYYYLTH-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ZALTOPROFEN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CN-100","Soreton","Zaltoprofen"],"crossReferences":{"PubChem":["144207183","170465838"],"drugbank":["DB06737"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL17879","canonicalSmiles":"CCCCC1(CCCC)CS(=O)(=O)c2ccc(N(C)C)cc2[C@@H](c2ccc(OCc3ccc(C[N+]45CCN(CC4)CC5)cc3)cc2)[C@H]1O.[Cl-]","inchiKey":"POMVPJBWDDJCMP-RUKDTIIFSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"MARALIXIBAT CHLORIDE","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL363392","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Livmarli"],"synonyms":["LUM-001","LUM001","Lopixibat chloride","Maralixibat chloride"],"linkedTargets":{"rows":["ENSG00000125255"],"count":1},"linkedDiseases":{"rows":["HP_0000989","EFO_0004268","Orphanet_52","EFO_1001486"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and is indicated for alagille syndrome and pruritus and has 2 investigational indications."}
{"id":"CHEMBL1801204","canonicalSmiles":"COc1ccc(-c2ccc3c(N4CCOC[C@@H]4C)nc(N4CCOC[C@@H]4C)nc3n2)cc1CO","inchiKey":"KVLFRAWTRWDEDF-IRXDYDNUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AZD-8055","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AZ-12600000","AZD 8055","AZD-8055","AZD8055","Azd-8055"],"crossReferences":{"drugbank":["DB12774"]},"linkedTargets":{"rows":["ENSG00000198793"],"count":1},"linkedDiseases":{"rows":["EFO_0000616","EFO_0000182","EFO_0000574","EFO_0002499","EFO_0002501","EFO_0000519","EFO_0000311"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of I (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL203631","canonicalSmiles":"CO[C@H]1CC[C@H](C(=O)Nc2cc(-c3ccnc(Nc4ccc(F)cc4)c3)ccn2)CC1","inchiKey":"ACGBFWCBVIXTPZ-OQIWPSSASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL203631","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08025"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2103742","drugType":"Small molecule","blackBoxWarning":false,"name":"MANGANESE SULFATE","yearOfFirstApproval":1987,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL1200557","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Manganese sulfate"],"synonyms":["Manganese sulfate","Manganum sulphuricum"],"crossReferences":{"DrugCentral":["4461"],"chEBI":["86364"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1987 and has 3 approved indications."}
{"id":"CHEMBL2103779","canonicalSmiles":"CN1CC(=O)N=C1NC(=O)Nc1cccc(Cl)c1.O","inchiKey":"UNFQKKSADLVQJE-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENOBAM","maximumClinicalTrialPhase":1,"parentId":"CHEMBL239800","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fenobam","MCN-3377-98"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2103798","canonicalSmiles":"COc1cc2c(Oc3ccc4[nH]c(C)cc4c3F)ncnc2cc1OCCCN1CCCC1.O=C(O)/C=C\\C(=O)O","inchiKey":"JRMGHBVACUJCRP-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEDIRANIB MALEATE","maximumClinicalTrialPhase":3,"parentId":"CHEMBL491473","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":["Recentin"],"synonyms":["AZD-2171 MALEATE","AZD2171 MALEATE","Cediranib maleat","Cediranib maleate"],"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 19 investigational indications."}
{"id":"CHEMBL2103929","canonicalSmiles":"CN(C)[C@@H]1C(O)=C(C(=O)NCNCCCC[C@H](N)C(=O)O)C(=O)[C@@]2(O)C(O)=C3C(=O)c4c(O)cccc4[C@@](C)(O)[C@H]3C[C@@H]12","inchiKey":"AHEVKYYGXVEWNO-UEPZRUIBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LYMECYCLINE","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tetralysal 150","Tetralysal 300"],"synonyms":["Ciclolysal","Ciclolysine","Lymecycline","Mucomycin","Tetracycline-l-methylenelysine","Tetracyclinemethylenelysine","Tetralysal"],"crossReferences":{"drugbank":["DB00256"],"chEBI":["59040"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and has 1 investigational indication."}
{"id":"CHEMBL2104200","canonicalSmiles":"CCCCN(CCN(CC)CC)C(=O)c1cccc2ccccc12","inchiKey":"WWGZXRYELYWJBD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUNAFTINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Bunaftine","Bunaphtide","Bunaphtine"],"crossReferences":{"drugbank":["DB13652"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2104906","canonicalSmiles":"CC12C=CC(C(=O)O[C@H]3CC[C@H]4[C@@H]5CCC6=CC(=O)CC[C@@H]6[C@H]5CC[C@]34C)(CC1)CC2","inchiKey":"REACBNMPQDINOF-YBBIQVIJSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NANDROLONE CYCLOTATE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nandrolone","Nandrolone cyclohexylpropionate","Nandrolone cyclotate","RS-3268R"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL2105424","canonicalSmiles":"Fc1cccc(Br)c1NC1=NCCN1","inchiKey":"KDPNLRQZHDJRFU-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"ROMIFIDINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Romifidine","Sedivet"],"crossReferences":{"drugbank":["DB11543"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2105750","canonicalSmiles":"C=C[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@@H](Oc2cc(-c3ccccc3)nc3cc(OC)ccc23)CN1C(=O)[C@@H](CC(=O)N1CCCCC1)C(C)(C)C)C(=O)NS(=O)(=O)C1CC1","inchiKey":"MHFMTUBUVQZIRE-WINRQGAFSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SOVAPREVIR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACH-0141625","Sovaprevir"],"crossReferences":{"drugbank":["DB12069"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2107374","canonicalSmiles":"O=C([O-])CCSC[C@H]1O[C@@H]2O[C@@H]3[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]4[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]5[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]6[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]7[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]8[C@@H](CSCCC(=O)[O-])O[C@H](O[C@@H]9[C@@H](CSCCC(=O)[O-])O[C@H](O[C@H]1[C@H](O)C2O)[C@H](O)[C@H]9O)[C@H](O)[C@H]8O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O)[C@H](O)[C@H]5O)[C@H](O)[C@H]4O)[C@H](O)[C@H]3O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+]","inchiKey":"KMGKABOMYQLLDJ-WXBCEIQXSA-F","drugType":"Oligosaccharide","blackBoxWarning":false,"name":"SUGAMMADEX SODIUM","yearOfFirstApproval":2015,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL2111107","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Bridion"],"synonyms":["ORG 25969","ORG-25969","Sugammadex octasodium salt","Sugammadex sodium"],"crossReferences":{"DailyMed":["sugammadex%20sodium"]},"description":"Oligosaccharide drug with a maximum clinical trial phase of IV that was first approved in 2015."}
{"id":"CHEMBL2107455","canonicalSmiles":"CS(=O)(=O)Nc1cc2occ(NC=O)c(=O)c2cc1Oc1ccccc1","inchiKey":"ANMATWQYLIFGOK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"IGURATIMOD","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Careram","Iguratimod","Kolbet","T-614"],"crossReferences":{"PubChem":["144206972"],"drugbank":["DB12233"]},"linkedTargets":{"rows":["ENSG00000056972","ENSG00000240972","ENSG00000073756"],"count":3},"linkedDiseases":{"rows":["EFO_0000685","EFO_0005761","EFO_0007160","EFO_0000699"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2108236","drugType":"Unknown","blackBoxWarning":false,"name":"CAPSICUM","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fiery jack"],"synonyms":["Ae-paprika","African chillies","B1353","B1666","B2636","Capsiate natura","Capsicum","Capsicum annuum","Capsicum annuum fruit","Capsicum annuum fruit extract","Capsicum annuum fruit liquid extract","Capsicum annuum fruit powder","Capsicum annuum tincture","Cayenne","Chile pepper","Chili pepper","Chilli pepper","Chillie pepper","FEMA NO. 2266","FEMA NO. 2833","Jalapeno pepper","Lajiao","Louisiana long pepper","Louisiana sport pepper","NDI 448","Paprika","Peppers, hot chili, green, raw","Peppers, hot chili, red, raw","Peppers, jalapeno, raw","Peppers,hot chili,grn,raw","Peppers,hot chili,red,raw","Peppers,jalapeno,raw","Spices, paprika"],"description":"Unknown drug with a maximum clinical trial phase of IV and has 1 investigational indication."}
{"id":"CHEMBL2108563","drugType":"Unknown","blackBoxWarning":false,"name":"SILICON DIOXIDE","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Silica gel","Silicon dioxide"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2108733","drugType":"Cell","blackBoxWarning":false,"name":"IXMYELOCEL-T","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ixmyelocel-t"],"description":"Cell drug with a maximum clinical trial phase of III (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL2108869","drugType":"Protein","blackBoxWarning":false,"name":"TIPLIMOTIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nbi-5788","Tiplimotide"],"description":"Protein drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2109085","drugType":"Antibody","blackBoxWarning":false,"name":"DETUMOMAB","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Detumomab","FAVID","SPECIFID"],"description":"Antibody drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL2109387","drugType":"Antibody","blackBoxWarning":false,"name":"PARSATUZUMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["MEGF-0444A","MEGF0444A","Parsatuzumab","RG-741","RG-7414","RG7414","anti-EGFL7 monoclonal antibody"],"linkedTargets":{"rows":["ENSG00000172889"],"count":1},"linkedDiseases":{"rows":["EFO_1001480","EFO_0003060","EFO_0000311"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL2109548","drugType":"Antibody","blackBoxWarning":false,"name":"MK-4721","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AGS-1C4D4","AGS-PSCA","MK-4721","Mk-4721"],"linkedTargets":{"rows":["ENSG00000167653"],"count":1},"linkedDiseases":{"rows":["EFO_0010282","EFO_0002517","MONDO_0008315"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL2135460","canonicalSmiles":"NCCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CSSC[C@H](NC(=O)CNC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](Cc2ccccc2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N1)C(=O)NCC(N)=O","inchiKey":"BENFXAYNYRLAIU-QSVFAHTRSA-N","drugType":"Protein","blackBoxWarning":false,"name":"TERLIPRESSIN","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Variquel"],"synonyms":["Glycylpressin","Glypressin","Terlipressin","Terlipressin acetate"],"crossReferences":{"PubChem":["124896640","144206925"],"drugbank":["DB02638"]},"childChemblIds":["CHEMBL4088899"],"description":"Protein drug with a maximum clinical trial phase of IV (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL227954","canonicalSmiles":"N#Cc1ccccc1Cn1c(N2CCC[C@@H](N)C2)nc2ccccc2c1=O","inchiKey":"OYNURZXTLNNKAP-QGZVFWFLSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL227954","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08588"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2308782","canonicalSmiles":"C[N+]1(C)[C@H]2CC[C@@H]1C[C@@H](CC(C#N)(c1ccccc1)c1ccccc1)C2.[Br-]","inchiKey":"CWRNUVNMUYSOFQ-ABHLOGGPSA-M","drugType":"Small molecule","blackBoxWarning":false,"name":"DAROTROPIUM BROMIDE","maximumClinicalTrialPhase":2,"parentId":"CHEMBL2365940","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Darotropium bromide","GSK-233705","GSK-233705B","GSK233705","GSK233705B"],"linkedTargets":{"rows":["ENSG00000180720","ENSG00000184984","ENSG00000133019","ENSG00000181072","ENSG00000168539"],"count":5},"linkedDiseases":{"rows":["EFO_0000341"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL2347655","canonicalSmiles":"CON(C)C(=O)N1N=C(c2cc(F)ccc2F)S[C@@]1(CCCN)c1ccccc1","inchiKey":"LLXISKGBWFTGEI-FQEVSTJZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FILANESIB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ARRY-520","Filanesib"],"crossReferences":{"drugbank":["DB06040"]},"childChemblIds":["CHEMBL3544920"],"linkedTargets":{"rows":["ENSG00000138160"],"count":1},"linkedDiseases":{"rows":["EFO_0000198","EFO_0000616","EFO_0006475","EFO_0000222","EFO_0001378"],"count":5},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL234838","canonicalSmiles":"N#Cc1c(NC(=O)c2ccccc2F)sc2c1CCCC2","inchiKey":"YVYPYORTKAIUGJ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"GW572738X","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["GW572738X"],"crossReferences":{"PubChem":["124349907"],"drugbank":["DB07217"],"chEBI":["40300"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL2387144","canonicalSmiles":"COc1cccc(/C=N/N(C(=O)C(F)(F)F)c2ccc(C)cc2C)c1","inchiKey":"HYMZAYGFKNNHDN-SSDVNMTOSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"J147","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["J-147","J147"],"crossReferences":{"drugbank":["DB13957"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL251935","canonicalSmiles":"Cc1c(CCO)c(=O)oc2cc(O)ccc12","inchiKey":"VCGFYFKJZGIZMX-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"OCIMARIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ocimarin"],"crossReferences":{"drugbank":["DB07908"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL254832","canonicalSmiles":"CC(NCCC(c1ccccc1)c1ccccc1)c1ccccc1","inchiKey":"NMKSAYKQLCHXDK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FENDILINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Fendiline"],"crossReferences":{"PubChem":["174006638"],"drugbank":["DB08980"]},"childChemblIds":["CHEMBL1405922"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL272621","canonicalSmiles":"C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@@H]3C[C@H](O)[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C","inchiKey":"DGABKXLVXPYZII-SIBKNCMHSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"HYODEOXYCHOLIC_ACID","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[".alpha.-hyodeoxycholic acid","AHRO-001","HDCA","Hyodeoxycholic acid","Hyodeoxycholic_acid","Hyodesoxycholic acid","NSC-60672"],"crossReferences":{"Wikipedia":["Hyodeoxycholic_acid"],"drugbank":["DB11789"],"chEBI":["52023"]},"linkedTargets":{"rows":["ENSG00000131408","ENSG00000025434"],"count":2},"linkedDiseases":{"rows":["HP_0003124"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL3544973","canonicalSmiles":"CC(=O)O.CCO/N=C(\\C(=O)N[C@@H]1C(=O)N2C(C(=O)[O-])=C(Sc3nc(-c4cc[n+](C)cc4)cs3)CS[C@H]12)c1nsc(NP(=O)(O)O)n1.O","inchiKey":"KRWPPVCZNGQQHZ-IINIBMQSSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CEFTAROLINE FOSAMIL ACETATE","yearOfFirstApproval":2010,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL501122","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Teflaro"],"synonyms":["Ceftaroine","Ceftaroline fosamil","Ceftaroline fosamil acetate","Ceftaroline fosamil monoacetate","Ppi-0903 monoacetate monohydrate","Tak-599 monoacetate monohydrate"],"crossReferences":{"chEBI":["70714"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2010 and is indicated for chronic kidney disease and bacterial pneumonia."}
{"id":"CHEMBL3545269","drugType":"Small molecule","blackBoxWarning":false,"name":"SAR425899","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Sar425899"],"linkedTargets":{"rows":["ENSG00000215644"],"count":1},"linkedDiseases":{"rows":["MONDO_0005148"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL3545313","canonicalSmiles":"CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O","inchiKey":"HYHMLYSLQUKXKP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BEMPEDOIC ACID","yearOfFirstApproval":2020,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Nexletol"],"synonyms":["Bempedoic acid","ESP-55016","ETC-1002","ETC1002"],"crossReferences":{"DailyMed":["bempedoic%20acid"],"drugbank":["DB11936"]},"linkedTargets":{"rows":["ENSG00000131473"],"count":1},"linkedDiseases":{"rows":["EFO_0003914","HP_0003124","MONDO_0021187","EFO_0001645","EFO_0000319","MONDO_0005148","EFO_0004911","Orphanet_309005"],"count":8},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2020 and has 4 approved and 4 investigational indications."}
{"id":"CHEMBL3545399","drugType":"Small molecule","blackBoxWarning":false,"name":"R-112","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["R-112","R-921218"],"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL3545406","drugType":"Small molecule","blackBoxWarning":false,"name":"LY2940094","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Ly2940094"],"linkedTargets":{"rows":["ENSG00000125510"],"count":1},"linkedDiseases":{"rows":["MONDO_0002050","MONDO_0002009","MONDO_0007079"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3647420","canonicalSmiles":"CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)/C=C/[C@H]1CCCN1C","inchiKey":"SADXACCFNXBCFY-IYNHSRRRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL3647420","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB14993"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3681419","canonicalSmiles":"Cc1onc(-c2ccc(F)cc2)c1COc1ccc(C(=O)N2CCS(=O)(=O)CC2)cn1","inchiKey":"VCGRFBXVSFAGGA-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BASMISANIL","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Basmisanil","RG-1662","RG1662","RO-5186582","RO5186582","Rg1662"],"crossReferences":{"drugbank":["DB11877"]},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL3707363","canonicalSmiles":"CC(CC(c1ccccc1)c1ccccc1)N(C)C","inchiKey":"NSHMKXVHJBBKTN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIMETHYLDIPHENYLPROPYLAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Trimethyldiphenylpropylamine"],"crossReferences":{"drugbank":["DB13361"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL374975","canonicalSmiles":"CC(=O)O[C@H]1C[C@@]2(C)[C@@H](C[C@@H](O)[C@H]3[C@@]4(C)CC[C@@H](O)[C@@H](C)[C@@H]4CC[C@@]32C)/C1=C(\\CCC=C(C)C)C(=O)O","inchiKey":"IECPWNUMDGFDKC-MZJAQBGESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"FUSIDIC ACID","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Fucidin caviject","Fucithalmic"],"synonyms":["Anhydrous fusidic acid","CEM-102","Fusidate","Fusidic acid","NSC-56192","Ramycin","SQ 16,603","SQ-16603","Taksta"],"crossReferences":{"Wikipedia":["Fusidic_acid"],"drugbank":["DB02703"],"chEBI":["29013"]},"childChemblIds":["CHEMBL1256987"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) and is indicated for bacterial disease and eye infection and has 5 investigational indications."}
{"id":"CHEMBL376185","canonicalSmiles":"CCC[C@@H]1C[C@@H](C(=O)NC(C(C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1","inchiKey":"KDLRVYVGXIQJDK-NOWPCOIGSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL376185","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01190"],"chEBI":["3745"]},"childChemblIds":["CHEMBL1490142"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL383570","canonicalSmiles":"O=C(O)C(=O)Nc1cc2ccccc2cc1C(=O)O","inchiKey":"DQBLKSRRWDWNKQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL383570","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB01734"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL384759","canonicalSmiles":"Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]2O)c(=O)[nH]1","inchiKey":"QGWNDRXFNXRZMB-UUOKFMHZSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL384759","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"PubChem":["26756683"],"Wikipedia":["Guanosine_diphosphate"],"drugbank":["DB04315"],"chEBI":["17552"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL386049","canonicalSmiles":"NS(=O)(=O)c1ccc(NC(=O)c2ccccc2S)cc1","inchiKey":"MRLVIVXGUGNENL-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-(2-Mercaptophenylcarboxamido)Benzenesulfonamide","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-(2-Mercaptophenylcarboxamido)Benzenesulfonamide"],"crossReferences":{"drugbank":["DB07476"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL3989871","canonicalSmiles":"Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F","inchiKey":"PUKBOVABABRILL-YZNIXAGQSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"AVACOPAN","yearOfFirstApproval":2021,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Tavneos"],"synonyms":["Avacopan","CCX-168","CCX168","Ccx168"],"crossReferences":{"drugbank":["DB15011"]},"linkedTargets":{"rows":["ENSG00000197405"],"count":1},"linkedDiseases":{"rows":["EFO_0006803","Orphanet_2134","EFO_1000710","EFO_0005297","MONDO_0015492","EFO_0004826","EFO_0004194","EFO_1000784","Orphanet_329918"],"count":9},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2021 and has 4 approved and 4 investigational indications."}
{"id":"CHEMBL404422","canonicalSmiles":"CCCCC1(CC)C(=O)NC(=O)NC1=O","inchiKey":"STDBAQMTJLUMFW-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BUTETHAL","maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Neonal","Soneryl"],"synonyms":["Butethal","Butobarbital","Butobarbitone","NSC-229336"],"crossReferences":{"Wikipedia":["Butobarbital"],"drugbank":["DB01353"]},"description":"Small molecule drug with a maximum clinical trial phase of IV."}
{"id":"CHEMBL405346","canonicalSmiles":"CSC[C@H]1CN(Cc2c[nH]c3c(N)ncnc23)C[C@@H]1O","inchiKey":"NTHMDFGHOCNNOE-ZJUUUORDSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL405346","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB08606"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL412531","canonicalSmiles":"CC[C@H](C)[C@@H](NC(=O)[C@@H](CCC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@@H](CO)NC(=O)[C@H](NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CS)C(C)C)C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(=O)O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C(=O)N[C@@H](C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(=O)O)C(=O)O)C(C)C)C(C)C)C(C)C)[C@H](C)O","inchiKey":"LCJVIYPJPCBWKS-NXPQJCNCSA-N","drugType":"Protein","blackBoxWarning":false,"name":"THYMOSIN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Thymosin"],"description":"Protein drug with a maximum clinical trial phase of III (across all indications) and has 7 investigational indications."}
{"id":"CHEMBL4297215","canonicalSmiles":"O=C1c2c(O)c(=O)ccn2N([C@@H]2c3ccccc3SCc3c2ccc(F)c3F)[C@@H]2COCCN12","inchiKey":"FIDLLEYNNRGVFR-CTNGQTDRSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"BALOXAVIR","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Baloxavir","S-033447"],"crossReferences":{"drugbank":["DB15675"]},"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4297539","name":"CHEMBL4297539","tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB12536"]}}
{"id":"CHEMBL4297570","drugType":"Unknown","blackBoxWarning":false,"name":"AMP-224","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Amp-224","Anti-pd-1 fusion protein amp-224","GSK-2661380"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4297668","canonicalSmiles":"CNC(=O)c1nn(C)c2c1C(C)(C)Cc1cnc(Nc3ccc(N4CCN(C)CC4)cc3)nc1-2.O=C(O)/C=C\\C(=O)O","inchiKey":"DGVCEXQFNYYRQI-BTJKTKAUSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"MILCICLIB MALEATE","maximumClinicalTrialPhase":1,"parentId":"CHEMBL564829","hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Milciclib maleate","PHA-848125AC","Pha-848125ac"],"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL4297817","drugType":"Unknown","blackBoxWarning":false,"name":"QS-21","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["QS21","Qs-21","Qs-21 adjuvant","SAPONIN QA-21V1","Stimulon"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 13 investigational indications."}
{"id":"CHEMBL4297868","drugType":"Enzyme","blackBoxWarning":false,"name":"RECOMBINANT HUMAN LECITHIN:CHOLESTEROL ACYLTRANSFERASE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ACP-501","Acp-501","MEDI-6012","MEDI6012","Medi 6012","Medi6012","Recombinant human lcat","Recombinant human lecithin:cholesterol acyltransferase","Rhlcat"],"description":"Enzyme drug with a maximum clinical trial phase of II (across all indications) and has 4 investigational indications."}
{"id":"CHEMBL4297988","drugType":"Enzyme","blackBoxWarning":false,"name":"IDURSULFASE BETA","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Hunterase","Idursulfase .beta.","Idursulfase beta"],"description":"Enzyme drug with a maximum clinical trial phase of III and has 1 investigational indication."}
{"id":"CHEMBL4298020","drugType":"Antibody","blackBoxWarning":false,"name":"LODAPOLIMAB","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["LY-3300054","LY3300054","Lodapolimab","Ly 3300054","Ly-3300054","Ly3300054"],"description":"Antibody drug with a maximum clinical trial phase of I (across all indications) and has 5 investigational indications."}
{"id":"CHEMBL4298045","drugType":"Antibody","blackBoxWarning":false,"name":"INDUSATUMAB VEDOTIN","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Indusatumab vedotin","MLN-0264","MLN0264","Mln0264","TAK-264"],"linkedTargets":{"rows":["ENSG00000261456","ENSG00000188229","ENSG00000104833","ENSG00000137267","ENSG00000258947","ENSG00000070019","ENSG00000101162","ENSG00000137285","ENSG00000196230","ENSG00000176014"],"count":10},"linkedDiseases":{"rows":["EFO_1000044","EFO_0000503","EFO_0000311"],"count":3},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL436559","canonicalSmiles":"CC(C)c1ccc(C(=O)N=C(N)N)cc1S(C)(=O)=O","inchiKey":"IWXNYAIICFKCTM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CARIPORIDE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Cariporide","HOE-642"],"crossReferences":{"Wikipedia":["Cariporide"],"drugbank":["DB06468"]},"childChemblIds":["CHEMBL462831"],"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL437","canonicalSmiles":"Nc1ccc(S(=O)(=O)Nc2nccs2)cc1","inchiKey":"JNMRHUJNCSQMMB-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SULFATHIAZOLE","yearOfFirstApproval":1945,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"]},"tradeNames":["Thiazamide"],"synonyms":["NSC-31812","NSC-683531","Sulfathiazole","Sulfathiazole (triple sulfa)","Sulphathiazole","Triple sulfa (sulfathiazole)"],"crossReferences":{"PubChem":["11112198","144203914","144209441","144213555","170465454","17388718","26747309","56463345","90559"],"Wikipedia":["Sulfathiazole"],"drugbank":["DB06147"],"chEBI":["9337"]},"childChemblIds":["CHEMBL3780934","CHEMBL2107243"],"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 1945 and is indicated for bacterial disease. It was withdrawn in United States."}
{"id":"CHEMBL4594503","drugType":"Antibody","blackBoxWarning":false,"name":"TALQUETAMAB","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["JNJ-63483043","JNJ-64407564","Talquetamab"],"linkedTargets":{"rows":["ENSG00000111291","ENSG00000167286","ENSG00000198851","ENSG00000160654"],"count":4},"linkedDiseases":{"rows":["EFO_0001642","EFO_0001378"],"count":2},"description":"Antibody drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4650375","drugType":"Unknown","blackBoxWarning":false,"name":"AT-100","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AT-100","AT100","At-100","Recombinant sp-d"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4650410","drugType":"Unknown","blackBoxWarning":false,"name":"NOVAFERON","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Nova (artificial interferon)","Novaferon","Recombinant interferon alpha 2b-like protein"],"description":"Unknown drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL467084","canonicalSmiles":"N[C@@H](Cc1ccccn1)c1ccccc1","inchiKey":"FWUQWDCOOWEXRY-ZDUSSCGKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"LANICEMINE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["AR-R15896AR","AZD-6765","AZD6765","Azd6765","Lanicemine"],"crossReferences":{"drugbank":["DB11889"]},"linkedTargets":{"rows":["ENSG00000161509","ENSG00000183454","ENSG00000273079","ENSG00000116032","ENSG00000105464","ENSG00000176884","ENSG00000198785"],"count":7},"linkedDiseases":{"rows":["MONDO_0002050","MONDO_0002009"],"count":2},"description":"Small molecule drug with a maximum clinical trial phase of II (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL4802147","canonicalSmiles":"C=C(C[C@H](NC(=O)c1ccc(CCc2ccc3nc(N)nc(N)c3c2)cc1)C(=O)O)C(=O)O","inchiKey":"NAWXUBYGYWOOIX-SFHVURJKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CH-1504 L-ISOMER","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["CH-4051","Ch-1504 l-isomer","Ch-4051","L-CH 1504","L-m-trex","L-mobiletrex"],"description":"Small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication."}
{"id":"CHEMBL4802185","drugType":"Unknown","blackBoxWarning":false,"name":"TTI-622","maximumClinicalTrialPhase":1,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["TTI-622","TTI622","Tti-622"],"description":"Unknown drug with a maximum clinical trial phase of I (across all indications) and has 2 investigational indications."}
{"id":"CHEMBL484785","canonicalSmiles":"N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1","inchiKey":"USZAGAREISWJDP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CRISABOROLE","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Eucrisa"],"synonyms":["AN-2728","AN2728","Crisaborole"],"crossReferences":{"DailyMed":["crisaborole"],"PubChem":["174007043"],"drugbank":["DB05219"]},"linkedTargets":{"rows":["ENSG00000065989","ENSG00000105650","ENSG00000113448","ENSG00000184588"],"count":4},"linkedDiseases":{"rows":["EFO_0004192","HP_0000964","EFO_1000764","MONDO_0002406","EFO_0000676","EFO_1001361","EFO_0000274"],"count":7},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and is indicated for eczema and atopic eczema and has 4 investigational indications."}
{"id":"CHEMBL502835","canonicalSmiles":"COC(=O)c1ccc2c(c1)NC(=O)/C2=C(\\Nc1ccc(N(C)C(=O)CN2CCN(C)CC2)cc1)c1ccccc1","inchiKey":"XZXHXSATPCNXJR-ZIADKAODSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NINTEDANIB","yearOfFirstApproval":2014,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Ofev","Vargatef"],"synonyms":["BIBF 1120","BIBF-1120","BIBF1120","Bibf-1120","Intedanib","Nintedanib"],"crossReferences":{"DailyMed":["nintedanib%20esylate"],"drugbank":["DB09079"],"chEBI":["85164"]},"childChemblIds":["CHEMBL3039504"],"linkedTargets":{"rows":["ENSG00000134853","ENSG00000128052","ENSG00000066468","ENSG00000068078","ENSG00000102755","ENSG00000077782","ENSG00000160867","ENSG00000037280","ENSG00000113721"],"count":9},"linkedDiseases":{"rows":["EFO_0007183","MONDO_0021117","EFO_0000768","EFO_0000681","EFO_0000571","MONDO_0007254","EFO_1001465","EFO_0000708","Orphanet_538","MONDO_0002087","MONDO_0044937","EFO_1001951","MONDO_0002158","EFO_0000588","EFO_0000389","EFO_1001331","EFO_0000182","EFO_0000770","EFO_0008528","EFO_0004244","EFO_0000673","MONDO_0008903","MONDO_0015277","EFO_0002499","EFO_0000717","EFO_1001949","EFO_0001416","EFO_0000616","EFO_0002618","EFO_0003893","EFO_0000503","MONDO_0008170","MONDO_0004669","EFO_0000222","EFO_0002501","EFO_0002500","EFO_0004243","EFO_0003060","EFO_0009448","MONDO_0100096","MONDO_0011962","MONDO_0001235","EFO_0004142","EFO_0000702","Orphanet_774","EFO_0004284","EFO_0001378","EFO_0000691","EFO_0000519"],"count":49},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2014 and has 3 approved and 45 investigational indications."}
{"id":"CHEMBL512341","canonicalSmiles":"COc1ccccc1-c1cc2c(c3c1C(=O)NC3=O)c1cc(O)ccc1n2CCCO","inchiKey":"AOGOZJCRIFBTTN-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CHEMBL512341","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":[],"crossReferences":{"drugbank":["DB07006"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL539423","canonicalSmiles":"CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1","inchiKey":"WRFHGDPIDHPWIQ-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"SPARSENTAN","maximumClinicalTrialPhase":3,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["PS-433540","PS433540","RE-021","Sparsentan"],"crossReferences":{"drugbank":["DB12548"]},"linkedTargets":{"rows":["ENSG00000151617","ENSG00000144891"],"count":2},"linkedDiseases":{"rows":["EFO_0004236","EFO_0004194","EFO_0000537"],"count":3},"description":"Small molecule drug with a maximum clinical trial phase of III (across all indications) and has 3 investigational indications."}
{"id":"CHEMBL540445","canonicalSmiles":"C=C1C(=O)O[C@H]2[C@H]1CC/C(C)=C/CC[C@@]1(C)O[C@@H]21","inchiKey":"KTEXNACQROZXEV-SLXBATTESA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PARTHENOLIDE","maximumClinicalTrialPhase":2,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["NSC-157035","Parthenolide"],"crossReferences":{"Wikipedia":["Parthenolide"],"drugbank":["DB13063"]},"description":"Small molecule drug with a maximum clinical trial phase of II."}
{"id":"CHEMBL560976","canonicalSmiles":"NC[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)O1","inchiKey":"JJCQSGDBDPYCEO-XVZSLQNASA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"DIBEKACIN","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["Dibekacin","Dibekacin sulfate"],"crossReferences":{"PubChem":["144205049"],"Wikipedia":["Dibekacin"],"drugbank":["DB13270"],"chEBI":["37945"]},"description":"Small molecule drug with a maximum clinical trial phase of I and has 1 investigational indication."}
{"id":"CHEMBL572","canonicalSmiles":"O=C1CN(/N=C/c2ccc([N+](=O)[O-])o2)C(=O)N1","inchiKey":"NXFQHRVNIOXGAQ-YCRREMRBSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"NITROFURANTOIN","yearOfFirstApproval":1953,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Berkfurin","Ceduran","Dantafur","Furadantin","Furalan","Genfura","Macrobid","Macrodantin","Nitrofurantoin","Nitrofurantoin (monohydrate/macrocrystals)","Nitrofurantoin macrocrystalline"],"synonyms":["Ivadantin","NSC-2107","NSC-44150","Nitrofurantoin","Nitrofurantoin anhydrous","Nitrofurantoin macrocrystal","Nitrofurantoin, macrocrystalline","Nitrofurantoin, macrocrystals","Nitrofurantoinum anhydrous"],"crossReferences":{"DailyMed":["nitrofurantoin","nitrofurantoin,%20macrocrystalline"],"PubChem":["17389788","26747377"],"TG-GATEs":["20"],"Wikipedia":["Nitrofurantoin"],"drugbank":["DB00698"],"chEBI":["71415"]},"childChemblIds":["CHEMBL1201000"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1953 and has 3 approved and 1 investigational indication."}
{"id":"CHEMBL609","canonicalSmiles":"NCCNCCNCCN","inchiKey":"VILCJCGEZXAXTO-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"TRIENTINE","yearOfFirstApproval":1985,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":[],"synonyms":["NSC-443","Syprine","Trethylenetetramine","Trientine","Triethylene tetraamine","Triethylene tetramine"],"crossReferences":{"DailyMed":["trientine%20hydrochloride"],"PubChem":["144204713","144208264","170465257","17389525"],"Wikipedia":["Triethylenetetramine"],"drugbank":["DB06824"],"chEBI":["39501"]},"childChemblIds":["CHEMBL1200783","CHEMBL3989777"],"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1985 and has 3 approved and 5 investigational indications."}
{"id":"CHEMBL7002","canonicalSmiles":"CC1(COc2ccc(CC3SC(=O)NC3=O)cc2)CCCCC1","inchiKey":"YZFWTZACSRHJQD-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"CIGLITAZONE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["ADD-3878","Ciglitazone","U-63,287","U-63287"],"crossReferences":{"PubChem":["144205673","170466553","26752160","26752161","26752162","26757865"],"Wikipedia":["Ciglitazone"],"drugbank":["DB09201"],"chEBI":["64227"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL79","canonicalSmiles":"CCN(CC)CC(=O)Nc1c(C)cccc1C","inchiKey":"NNJVILVZKWQKPM-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"LIDOCAINE","yearOfFirstApproval":1948,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Alphacaine","Anestacon","Dentipatch","Lidocaine","Lidoderm","Lignocaine Hcl","Lignostab","Lmx 4","Oraqix","Vagisil","Xylocaine","Xylodase","Xylotox","Ztlido"],"synonyms":["ALGRX 3268","ALGRX-3268","Anestacon","Embolex","Iontocaine","Lidocaine","Lidocainum","Lidocaton","Lidopen","Lignocaine","NSC-40030","Octocaine","Solarcaine","Xylestesin"],"crossReferences":{"DailyMed":["lidocaine","lidocaine%20hydrochloride"],"PubChem":["104171182","11111384","11111385","144203734","170464729","26751483","26751484","56422194","855682","90340642"],"Wikipedia":["Lidocaine"],"drugbank":["DB00281"],"chEBI":["6456"]},"childChemblIds":["CHEMBL3278065","CHEMBL541521","CHEMBL1200409"],"linkedTargets":{"rows":["ENSG00000185313","ENSG00000196876","ENSG00000183873","ENSG00000136546","ENSG00000144285","ENSG00000169432","ENSG00000168356","ENSG00000136531","ENSG00000007314","ENSG00000153253"],"count":10},"linkedDiseases":{"rows":["EFO_1000910","EFO_0001361","EFO_0002610","EFO_0010822","EFO_1001178","EFO_0009540","HP_0030838","EFO_0007486","EFO_0000555","MONDO_0002959","EFO_0005952","EFO_0005773","EFO_1001951","HP_0100543","EFO_0003103","EFO_0003931","MONDO_0016047","EFO_1001366","EFO_0009582","MONDO_0008903","EFO_0004616","EFO_0009620","EFO_0000400","EFO_1001904","MONDO_0002635","EFO_0005762","EFO_0003888","EFO_0002618","EFO_1000864","HP_0012532","HP_0002619","EFO_0002496","EFO_0001663","MONDO_0100431","HP_0002027","EFO_0000546","MP_0001914","MONDO_0002691","EFO_0009688","EFO_0003957","HP_0000951","EFO_0000574","HP_0100607","MONDO_0002258","EFO_1001887","EFO_1001434","EFO_0003943","MONDO_0018373","EFO_1001896","EFO_0005687","EFO_0001365","MONDO_0007254","EFO_0000284","EFO_0008568","EFO_0009430","EFO_0003100","EFO_1001996","EFO_0004143","EFO_0001069","EFO_0000707","EFO_1000249","EFO_1002005","EFO_0000616","EFO_0004799","EFO_0004210","EFO_0004269","EFO_0001645","EFO_0003958","EFO_0003898","EFO_0004198","EFO_0000319","HP_0003418","EFO_0001073","EFO_0003843","HP_0002315","EFO_0000537","HP_0000713","EFO_0007149","HP_0001082","EFO_1001412","EFO_0010582","EFO_0000649","EFO_1001087","HP_0004308","HP_0000020","EFO_0004273","MONDO_0043510","MONDO_0001572","MONDO_0005178","EFO_0000519","EFO_0009492","EFO_0003777","HP_0000989","EFO_1001139","MONDO_0041052","HP_0012735","MONDO_0004567","EFO_1001919","EFO_0000565","EFO_1000889","Orphanet_365","MONDO_0002471","EFO_0000544","EFO_1001898","HP_0003419","EFO_0009552","EFO_1000789","HP_0000737","EFO_1001250","HP_0000360","EFO_0001074","EFO_0005856","HP_0009762","EFO_0000701","EFO_0009516","EFO_0003878","EFO_0000294","HP_0003326","MP_0001845","MONDO_0100096","EFO_1001240","HP_0030833","EFO_0000731","EFO_0004888","EFO_0009951","EFO_0003033","EFO_0009676","HP_0030680","EFO_0000668","EFO_0005251","EFO_0002970","EFO_0009660","EFO_1001998","EFO_1001219","EFO_0006834","EFO_1001435","EFO_0008507","EFO_0009846","EFO_0000305","EFO_0002950","EFO_0003902","MONDO_0005277","EFO_1000783","HP_0030834","EFO_0000712","MONDO_0005129","EFO_0009619","EFO_1001993","EFO_0003932","EFO_0002460","EFO_0005279","EFO_0003917","EFO_0003030","EFO_0005230","EFO_1000362","HP_0001822","EFO_0007490","EFO_0000545","EFO_0000313","HP_0003394","EFO_0003894","EFO_1001054","EFO_1000941","EFO_0007214","EFO_0005754","EFO_0000311","EFO_1001097","HP_0001907","EFO_0003890","EFO_0003901","MONDO_0005301","EFO_0003854","EFO_0009364","EFO_0004142","EFO_1000781","EFO_0005611","EFO_0003833"],"count":177},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1948 and has 22 approved and 96 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL79512","canonicalSmiles":"NCCCCc1ccccc1","inchiKey":"AGNFWIZBEATIAK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"4-PHENYL-BUTYLAMINE","maximumClinicalTrialPhase":0,"hasBeenWithdrawn":false,"isApproved":false,"tradeNames":[],"synonyms":["4-Phenyl-Butylamine","4-Phenylbutylamine"],"crossReferences":{"drugbank":["DB04311"]},"description":"Small molecule drug with a maximum clinical trial phase of I."}
{"id":"CHEMBL813","canonicalSmiles":"CCCCc1ncc(/C=C(\\Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1","inchiKey":"OROAFUQRIXKEMV-LDADJPATSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"EPROSARTAN","yearOfFirstApproval":1997,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Teveten"],"synonyms":["Eprosartan","SK&F 108566","SK&F-108566","SK-108566","Teveten"],"crossReferences":{"DailyMed":["eprosartan%20mesylate"],"Wikipedia":["Eprosartan"],"drugbank":["DB00876"],"chEBI":["4814"]},"childChemblIds":["CHEMBL1200987"],"linkedTargets":{"rows":["ENSG00000144891"],"count":1},"linkedDiseases":{"rows":["EFO_0003086","MONDO_0001134","EFO_0000319","EFO_0000537"],"count":4},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1997 and is indicated for cardiovascular disease and hypertension and has 2 investigational indications. This drug has a black box warning from the FDA."}
{"id":"CHEMBL865","canonicalSmiles":"Cc1onc(-c2ccccc2)c1-c1ccc(S(N)(=O)=O)cc1","inchiKey":"LNPDTQAFDNKSHK-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"VALDECOXIB","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":true,"isApproved":true,"withdrawnNotice":{"countries":["United States"],"classes":["Cardiotoxicity"," Neurotoxicity"],"year":2004},"tradeNames":["Bextra"],"synonyms":["NSC-759846","SC-65872","Valdecoxib","Valdyn"],"crossReferences":{"PubChem":["144204991","170465163","26748964","49665731"],"Wikipedia":["Valdecoxib"],"drugbank":["DB00580"],"chEBI":["63634"]},"linkedTargets":{"rows":["ENSG00000073756"],"count":1},"linkedDiseases":{"rows":["EFO_0000685","EFO_0000278","EFO_0004616","HP_0003419","HP_0100607","EFO_1002012","MONDO_0002258","EFO_0003843","MONDO_0005178","EFO_0005755"],"count":10},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2001 and is indicated for rheumatic disease and has 5 investigational indications. It was withdrawn in United States  in 2004 due to Cardiotoxicity and  Neurotoxicity. This drug has a black box warning from the FDA."}
{"id":"CHEMBL904","canonicalSmiles":"COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1.Cl","inchiKey":"JUMYIBMBTDDLNG-OJERSXHUSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DEXMETHYLPHENIDATE HYDROCHLORIDE","yearOfFirstApproval":2001,"maximumClinicalTrialPhase":4,"parentId":"CHEMBL827","hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dexmethylphenidate hydrochloride","Focalin","Focalin xr"],"synonyms":["Dexmethylphenidate hcl","Dexmethylphenidate hydrochloride","Methylphenidate d-threo-form hydrochloride"],"crossReferences":{"DailyMed":["dexmethylphenidate%20hydrochloride"]},"linkedTargets":{"rows":["ENSG00000103546","ENSG00000142319"],"count":2},"linkedDiseases":{"rows":["EFO_0003888"],"count":1},"description":"Small molecule drug with a maximum clinical trial phase of IV that was first approved in 2001 and is indicated for attention deficit hyperactivity disorder. This drug has a black box warning from the FDA."}
{"id":"CHEMBL90593","canonicalSmiles":"C[C@]12CC[C@H]3[C@@H](CC=C4C[C@@H](O)CC[C@@]43C)[C@@H]1CCC2=O","inchiKey":"FMGSKLZLMKYGDP-USOAJAOKSA-N","drugType":"Small molecule","blackBoxWarning":false,"name":"PRASTERONE","yearOfFirstApproval":2016,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Dhea","Enzymatic therapy","Intrarosa","Natrol dhea"],"synonyms":["Biolaif","Dehydroandrosterone","Dehydroepiandrosterone","Dehydroisoandrosterone","EM-760","NSC-9896","Prasterone","Vaginorm"],"crossReferences":{"DailyMed":["prasterone"],"PubChem":["144204773","144209194","144213078","170465614","26753548","29215152","50106135","50106136","56320669","75250"],"Wikipedia":["Dehydroepiandrosterone"],"drugbank":["DB01708"],"chEBI":["28689"]},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 2016 and has 8 approved and 25 investigational indications."}
{"id":"CHEMBL964","canonicalSmiles":"CCN(CC)C(=S)SSC(=S)N(CC)CC","inchiKey":"AUZONCFQVSMFAP-UHFFFAOYSA-N","drugType":"Small molecule","blackBoxWarning":true,"name":"DISULFIRAM","yearOfFirstApproval":1951,"maximumClinicalTrialPhase":4,"hasBeenWithdrawn":false,"isApproved":true,"tradeNames":["Antabuse","Disulfiram","Esperal"],"synonyms":["Disulfiram","NSC-25953","ORA-102","ORA102"],"crossReferences":{"DailyMed":["disulfiram"],"PubChem":["104171249","11111859","11111860","11533044","123060006","124881563","124881565","124881567","124881570","144203831","144210721","144214033","170464767","26747681","26747682","26753660","26753661","50107088","50107089","56422197","85231246","90340564"],"TG-GATEs":["109"],"Wikipedia":["Disulfiram"],"drugbank":["DB00822"],"chEBI":["4659"]},"linkedTargets":{"rows":["ENSG00000111275"],"count":1},"linkedDiseases":{"rows":["EFO_0002610","EFO_0000756","MONDO_0007254","EFO_0001073","MONDO_0008315","EFO_0003060","EFO_0000311","EFO_1000044","MONDO_0100096","MONDO_0021698","EFO_0000764","EFO_0000514","EFO_0005611","EFO_0004701","MONDO_0007079","HP_0012378","EFO_0001378","EFO_0000691","EFO_0000519","EFO_0001067","EFO_0002617"],"count":21},"description":"Small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1951 and is indicated for parasitic infection and alcohol dependence and has 15 investigational indications. This drug has a black box warning from the FDA."}
